Barbara J. Farrell

Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. Supporting Information Filename Description bcpt_70235-sup-0001-Supplementary_Information.docxWord 2007 document , 6 MB Appendix A: Checklist for Reporting of Survey Studies (CROSS). Appendix B: Survey Questions. Appendix C: List of organisations based on published endorsement information.

COI conflict of interest ICOD International Conference on Deprescribing MedTech company medical technology company 1 Introduction and Background Deprescribing—the planned and supervised process of dose reduction or stopping of medications that may no longer be beneficial or may be causing harm [1]—has emerged as a crucial strategy to address the growing challenge of inappropriate polypharmacy [2, 3].

1 INTRODUCTION Medications with anticholinergic effects are widely used among older people despite evidence of functional and cognitive harm.1 Anticholinergic-induced cognitive impairment may be caused by antagonism of the effect of the neurotransmitter acetylcholine in the central nervous system.2 Such impairment is likely to be partially reversible upon cessation3 but anticholinergic deprescribing can be challenging.